KLK2 directed T cell engager therapeutic (EpimAb Biotherapeutics/Juri Biosciences)

N/A

Report date: 2026/03/19 17:11:57

Base Information

Drug NameKLK2 directed T cell engager therapeutic (EpimAb Biotherapeutics/Juri Biosciences)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionKallikrein 2 modulatorsT cell surface glycoprotein CD3 modulators
TargetsKallikrein 2T cell surface glycoprotein CD3
Therapy Area/IndicationsProstatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesEpimab Biotherapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesJuri Biosciences IncEpimab Biotherapeutics Inc
Inactive CompaniesN/A
Active IndicationsProstatic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A